Mark H. Rozenbaum
YOU?
Author Swipe
View article: Healthcare providers’ preferences for pediatric pneumococcal vaccination recommendations in the United States
Healthcare providers’ preferences for pediatric pneumococcal vaccination recommendations in the United States Open
HCPs' choices indicated a preference for the use of PCV20 in both a clinical setting and in pediatric pneumococcal vaccination recommendations, due to the higher number of serotypes covered by PCV20.
View article: Conceptual Methodological Framework for Incorporating Antimicrobial Resistance Considerations in Economic Models for Pneumococcal Conjugate Vaccines
Conceptual Methodological Framework for Incorporating Antimicrobial Resistance Considerations in Economic Models for Pneumococcal Conjugate Vaccines Open
View article: A Novel Approach to Estimate the Impact of PCV20 Immunization in Children by Incorporating Indirect Effects to Generate the Number Needed to Vaccinate
A Novel Approach to Estimate the Impact of PCV20 Immunization in Children by Incorporating Indirect Effects to Generate the Number Needed to Vaccinate Open
Background/Objectives: The number needed to vaccinate (NNV) is a metric commonly used to evaluate the public health impact of a vaccine as it represents the number of individuals that must be vaccinated to prevent one case of disease. Trad…
View article: Disparities in invasive pneumococcal disease, pneumonia, and otitis media among US children by comorbidity profile and insurance status
Disparities in invasive pneumococcal disease, pneumonia, and otitis media among US children by comorbidity profile and insurance status Open
Background Near-universal pediatric use of pneumococcal conjugate vaccines in the United States (US) has yielded substantive reductions childhood invasive pneumococcal disease (IPD), pneumonia (PNE), and otitis media (OM), especially among…
View article: Cost of invasive pneumococcal disease, all-cause pneumonia, and all-cause otitis media among commercial-insured US children
Cost of invasive pneumococcal disease, all-cause pneumonia, and all-cause otitis media among commercial-insured US children Open
Costs of IPD, all-cause PNE, and all-cause OM are high, particularly in the hospital setting. All-cause PNE, one of the most common causes of hospitalization for children, is particularly costly for children with comorbidities.
View article: P-629. The Health and Economic Impact of the PCV15 and PCV20 Priming Series during the First Year of Life in the US
P-629. The Health and Economic Impact of the PCV15 and PCV20 Priming Series during the First Year of Life in the US Open
Background Two pneumococcal conjugate vaccines, 15- (PCV15) and 20- (PCV20) valent formulations, are currently recommended for US infants in a 3+1 schedule. The first 3 doses are administered during the first year of life (‘priming doses’ …
View article: The Health and Economic Effects of PCV15 and PCV20 During the First Year of Life in the US
The Health and Economic Effects of PCV15 and PCV20 During the First Year of Life in the US Open
(1) Background/Objectives: Two pneumococcal conjugate vaccines, 15-(PCV15) and 20-(PCV20) valent formulations, are routinely recommended for US children in a 3+1 schedule. The first three doses are administered during the first year of lif…
View article: Pediatric Pneumococcal Conjugate Vaccine and Dosing Schedule Perceptions Among Health Care Providers and Caregivers in Germany, France, Spain, and Greece
Pediatric Pneumococcal Conjugate Vaccine and Dosing Schedule Perceptions Among Health Care Providers and Caregivers in Germany, France, Spain, and Greece Open
View article: Respiratory Syncytial Virus Sequelae Among Adults in High-Income Countries: A Systematic Literature Review and Meta-analysis
Respiratory Syncytial Virus Sequelae Among Adults in High-Income Countries: A Systematic Literature Review and Meta-analysis Open
View article: Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13
Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13 Open
A PCV20 catch-up program could prevent pneumococcal infections, antibiotic prescriptions, and antimicrobial-resistant infections and would be cost-saving in the US.
View article: Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions Open
Use of PCV20 among young children with CMC+ and IC in the USA would reduce the clinical burden of pneumococcal disease and yield overall cost savings from both the US healthcare system and societal perspectives. Higher PCV20 uptake could f…
View article: Supplementary materials: Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy
Supplementary materials: Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy Open
These are peer-reviewed supplementary tables for the article 'Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy' published in the Journal of Comparati…
View article: Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile
Rates of Lower Respiratory Tract Illness in US Adults by Age and Comorbidity Profile Open
Incidence of LRTI, including that due to RSV, especially for events requiring acute inpatient care, is markedly higher among older adults and adults of all ages with CMC or IC.
View article: Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants Open
Infant vaccination with PCV20 is estimated to further reduce pneumococcal disease and associated healthcare system and societal costs compared to both PCV13 and PCV15.
View article: 1737. Cost-Effectiveness Analysis of Catch-Up Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine
1737. Cost-Effectiveness Analysis of Catch-Up Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine Open
Background A 20-valent pneumococcal vaccine (PCV20) was approved in April 2023 by the US FDA for use in children < 18 years of age. Routine use in infants consists of a 3-dose schedule followed by a booster dose between 12 and 15 months…
View article: 1738. Cost-Effectiveness Analysis of Infant Pneumococcal Vaccination with the 20-Valent Pneumococcal Conjugate in the US
1738. Cost-Effectiveness Analysis of Infant Pneumococcal Vaccination with the 20-Valent Pneumococcal Conjugate in the US Open
Background As of March 2023, two pneumococcal conjugate vaccines, 13- (PCV13) and 15- (PCV15) valent formulations, are recommended for US infants under a 3+1 schedule. PCV20 was approved by the FDA in June of 2021 for adults ≥18 years and …
View article: Pediatric Respiratory Syncytial Virus Diagnostic Testing Performance: A Systematic Review and Meta-analysis
Pediatric Respiratory Syncytial Virus Diagnostic Testing Performance: A Systematic Review and Meta-analysis Open
Background Adding additional specimen types (eg, serology or sputum) to nasopharyngeal swab (NPS) reverse transcription polymerase chain reaction (RT-PCR) increases respiratory syncytial virus (RSV) detection among adults. We assessed if a…
View article: Incidence of Respiratory Syncytial Virus Infection in Older Adults: Limitations of Current Data
Incidence of Respiratory Syncytial Virus Infection in Older Adults: Limitations of Current Data Open
View article: Reanalysis of the Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children < 5 Age: A Societal Perspective
Reanalysis of the Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children < 5 Age: A Societal Perspective Open
The inclusion of non-medical costs nearly tripled the total economic burden compared with only including direct medical costs estimated from a previous study. The results from this reanalysis can help inform decision-makers on the broader …
View article: Low Levels of RSV Testing Among Adults Hospitalized for Lower Respiratory Tract Infection in the United States
Low Levels of RSV Testing Among Adults Hospitalized for Lower Respiratory Tract Infection in the United States Open
A small proportion of older adults hospitalized with LRTI are tested for RSV in US hospitals. Large variability occurs across hospital types. Consequently, retrospective database analyses likely result in a substantial underestimation of t…
View article: Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis
Underascertainment of Respiratory Syncytial Virus Infection in Adults Due to Diagnostic Testing Limitations: A Systematic Literature Review and Meta-analysis Open
Background Most observational population-based studies identify respiratory syncytial virus (RSV) by nasal/nasopharyngeal swab reverse transcriptase real-time PCR (RT-PCR) only. We conducted a systematic review and meta-analyses to quantif…
View article: 2207. Rates of Lower Respiratory Tract Infections Among US Adults Aged ≥18 Years With and Without Chronic Medical Conditions
2207. Rates of Lower Respiratory Tract Infections Among US Adults Aged ≥18 Years With and Without Chronic Medical Conditions Open
Background While it is widely recognized that older adults and adults with chronic medical conditions are at increased risk of lower respiratory tract infections (LRTI), available evidence on the magnitude of increased risk is limited. Met…
View article: A Response to: Letter to the Editor Regarding ‘Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age’
A Response to: Letter to the Editor Regarding ‘Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age’ Open
View article: The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data
The Effect of the Drug Life Cycle Price on Cost-Effectiveness: Case Studies Using Real-World Pricing Data Open
Assuming dynamic drug prices may lead to more representative ICER estimates. Future CEAs for drugs could account for predicted and disaggregated life cycle price developments based on retrospective data.
View article: Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries
Prevalence, characteristics, and mortality of patients with transthyretin amyloid cardiomyopathy in the Nordic countries Open
Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is a progressive condition caused by deposition of transthyretin amyloid fibrils in the heart and is associated with poor quality of life and a shortened lifespan. This study aimed to des…
View article: Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?
Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose? Open
View article: Healthcare resource use of patients with transthyretin amyloid cardiomyopathy
Healthcare resource use of patients with transthyretin amyloid cardiomyopathy Open
Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is the cardiac manifestation of transthyretin amyloidosis (ATTR). The aim of this study was to estimate healthcare resource use for ATTR‐CM patients compared with heart failure (HF) patie…
View article: Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy
Annual Cardiovascular-Related Hospitalization Days Avoided with Tafamidis in Patients with Transthyretin Amyloid Cardiomyopathy Open
View article: Supplementary Material for: Estimating the effect of tafamidis on cardiovascular-related hospitalization in NYHA class III patients with transthyretin amyloid cardiomyopathy in the presence of death
Supplementary Material for: Estimating the effect of tafamidis on cardiovascular-related hospitalization in NYHA class III patients with transthyretin amyloid cardiomyopathy in the presence of death Open
Background: The Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) demonstrated the effectiveness of tafamidis for the treatment of patients with transthyretin amyloid cardiomyopathy (ATTR-CM). Tafamidis reduced mortality …
View article: POSC112 The Effect of the Drug Life Cycle Price on Cost-Effectiveness Results: A Real-World Data Analysis
POSC112 The Effect of the Drug Life Cycle Price on Cost-Effectiveness Results: A Real-World Data Analysis Open